Teva sees growth in 2012 and authorises $3 billion buyback
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries has predicted that its sales will rise in 2012, and says it should be able to improve on the lack of US generic launches in 2011 –the US remains Teva's largest and most important generic market.